About NeuraLace Medical

NeuraLace offers Axon Therapy®, a 100% non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed to treat chronic neuropathic pain without the need for needles or surgical interventions. This technology provides significant pain reduction, minimizing reliance on opioids and improving patient quality of life through targeted neuromodulation.

```xml <problem> Chronic neuropathic pain is commonly treated with medications, including opioids, or invasive procedures, which may lead to adverse side effects, addiction, or surgical complications. Existing neuromodulation techniques often require injections, implants, or ablations, posing risks of infection and therapeutic interruptions. </problem> <solution> NeuraLace offers Axon Therapy, a non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed for treating chronic neuropathic pain. The device delivers high-intensity magnetic pulses at skin level to recondition the central nervous system by eliminating noxious pain signals. This approach provides a pain-free alternative to traditional methods, minimizing the need for opioids and other medications while improving patient quality of life. The mPNS mechanism of action is FDA-cleared for post-surgery and post-trauma neuromodulation. </solution> <features> - 100% non-invasive neuromodulation without needles, scalpels, or implants - High-intensity magnetic field administered at or above skin level - Reconditions the central nervous system by eliminating noxious pain signals - Spot treatments with an average of 60% pain reduction after complete treatment protocol (respondent patients only, VA Augusta Clinical Equipment Evaluation (CEC)) - FDA-cleared for post-surgery and post-trauma neuromodulation </features> <target_audience> The primary audience includes patients suffering from chronic neuropathic pain, as well as healthcare providers seeking non-invasive alternatives to traditional pain management methods. </target_audience> ```

What does NeuraLace Medical do?

Where is NeuraLace Medical located?

NeuraLace Medical is based in San Diego, United States.

When was NeuraLace Medical founded?

NeuraLace Medical was founded in 2016.

How much funding has NeuraLace Medical raised?

NeuraLace Medical has raised 15130000.

Location

San Diego, United States

Founded

2016

Funding

15130000

Employees

14 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

NeuraLace Medical

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

neuralacemedical.com 2K+

Founded 2016 – San Diego, United States

Funding

Estimated Funding

$10M+

Team (10+)

No team information available.

Company Description

Problem

Chronic neuropathic pain is commonly treated with medications, including opioids, or invasive procedures, which may lead to adverse side effects, addiction, or surgical complications. Existing neuromodulation techniques often require injections, implants, or ablations, posing risks of infection and therapeutic interruptions.

Solution

NeuraLace offers Axon Therapy, a non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed for treating chronic neuropathic pain. The device delivers high-intensity magnetic pulses at skin level to recondition the central nervous system by eliminating noxious pain signals. This approach provides a pain-free alternative to traditional methods, minimizing the need for opioids and other medications while improving patient quality of life. The mPNS mechanism of action is FDA-cleared for post-surgery and post-trauma neuromodulation.

Features

100% non-invasive neuromodulation without needles, scalpels, or implants

High-intensity magnetic field administered at or above skin level

Reconditions the central nervous system by eliminating noxious pain signals

Spot treatments with an average of 60% pain reduction after complete treatment protocol (respondent patients only, VA Augusta Clinical Equipment Evaluation (CEC))

FDA-cleared for post-surgery and post-trauma neuromodulation

Target Audience

The primary audience includes patients suffering from chronic neuropathic pain, as well as healthcare providers seeking non-invasive alternatives to traditional pain management methods.